Immunovant (IMVT) Stock
Clinical biotech developing treatments for autoimmune diseases. Here's the price, business snapshot, and what's worth knowing about Immunovant in July 2026.
Immunovant Inc (IMVT) is a clinical-stage biotechnology company developing targeted therapies for autoantibody-driven diseases. The firm focuses on modulating the neonatal Fc receptor (FcRn) pathway to reduce pathogenic antibodies, aiming to address conditions such as myasthenia gravis and other autoimmune disorders. For investors, key things to know are that Immunovant’s value is heavily linked to clinical trial readouts, regulatory decisions and any partnership or commercialisation arrangements. As a research-driven biotech, it typically has limited or no product revenue and carries higher volatility and binary risk: positive trial news can re-rate the stock, while setbacks may weigh heavily on the share price. Financial runway, trial timelines and competitive positioning in the FcRn space are important monitoring points. The stock may suit investors seeking exposure to potential breakthrough therapies but who understand clinical, regulatory and dilution risks; it is not a substitute for personalised financial advice and past performance does not guarantee future returns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Immunovant's stock with a target price of $39.07, suggesting growth potential.
Financial Health
Immunovant is performing well with strong cash flow and solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring IMVT
Oncology Repurposing: Could Autoimmune Buyouts Surge?
Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.175 billion to secure its advanced T-cell engager therapies. This strategic buyout reflects a growing industry trend of repurposing oncology technologies to treat severe autoimmune diseases.
Published: 24 March 2026
Explore BasketRinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published: 21 October 2025
Explore BasketPharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: 29 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical readouts matter
Trial results and regulatory milestones are primary value drivers and can move the stock significantly, though binary outcomes can increase volatility.
Targeted mechanism focus
A focus on FcRn modulation addresses multiple antibody-driven diseases, offering upside if programmes succeed, while competition and safety remain considerations.
Market opportunity & risks
Autoimmune indications represent a sizeable market, but commercial success depends on approvals, pricing, and adoption; investors should weigh upside against financing and regulatory risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
